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Abstract: In this study, bovine lactoferrin (bLf), an iron-binding glycoprotein considered an important
nutraceutical protein because of its several properties, was expressed in Pichia pastoris KM71-H
under AOX1 promoter control, using pJ902 as the recombinant plasmid. Dot blotting analysis
revealed the expression of recombinant bovine lactoferrin (rbLf) in Pichia pastoris. After Bach
fermentation and purification by molecular exclusion, we obtained an expression yield of 3.5 g/L
of rbLf. rbLf and predominantly pepsin-digested rbLf (rbLfcin) demonstrated antibacterial activity
against Escherichia coli (E. coli) BL21DE3, Staphylococcus aureus (S. aureus) FRI137, and, in a smaller
percentage, Pseudomonas aeruginosa (Ps. Aeruginosa) ATCC 27833. The successful expression and
characterization of functional rbLf expressed in Pichia pastoris opens a prospect for the development
of natural antimicrobial agents produced recombinantly.
Keywords: recombinant bovine lactoferrin; lactoferricin; antibacterial activity; Pichia pastoris
1. Introduction
Milk is a fluid produced by females of all mammal species whose main function is to be the first
food of a newborn because it supplies all the nutritional requirements of the newborn to contribute to
organ development and the maintenance of normal physiology [1,2].
Lactoferrin (Lf) was first identified in milk in 1939 by Sorensen [3] and the first reports reference
it as “red protein from milk” [4]. It is an 80-kDa iron-binding glycoprotein belonging to the transferrin
family. It is found in high concentrations in colostrum and milk, and in lower amounts in mucosal
secretions such as tears, saliva, semen, nasal and bronchial secretions, bile, and gastrointestinal
fluids [5]. On the other hand, lactoferrin is also a constitutive component of neutrophils; it is released
from them in the inflammatory process. Therefore, its concentration is elevated in inflammatory,
neurodegenerative, and inflammatory diseases, such as arthritis and the allergic process. Lf is
known because of its ability to modulate the immune response. Currently, the mechanism to exert
its immunomodulatory activity is not well elucidated; however, reports suggest that Lf is able to
recruit several immune cells, as well as promote the balance of the production of these cells [6].
Other important functions of Lf are related to its antimicrobial effects which have been demonstrated
in vivo and in vitro [7]. Lf is capable of affecting the proliferation of several microorganisms with
clinical importance, including Gram-positive and -negative bacteria, and viruses such as HIV, parasites,
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and fungi [8,9]. The antibacterial effect of Lf has been noticeably more studied; bioactive peptides of Lf
have the ability to bind to some molecules of the cell membrane, causing instability and subsequent cell
disruption. Moreover, its capacity to sequester iron allows competition for nutrients with siderophores,
avoiding their growth and proliferation [10,11]. Other qualities render Lf a multifunctional protein,
such as its anticarcinogenic and enzymatic activity [5].
Lf has been named “nutraceutical protein” because of its remarkable potential to have multiple
properties and the potential for use as a therapeutic protein [12]; it is considered one of the most
produced recombinantly [13,14]. Lf has been expressed in several microscopic models. Our research
group has expressed bovine lactoferrin (bLf) using an Escherichia coli (E. coli) model expression system,
and we obtained functional antibacterial activity fractions of bLf [15]; however, the use of prokaryotic
systems presents disadvantages which can be avoided by using eukaryotic systems—for example, the
protein toxicity could interfere with growth and cause cell death [16].
In the pharmaceutical industry, yeast-based expression systems are highly valued. In recent years,
the production of recombinant proteins has increasingly focused on the yeast. Pichia pastoris (P. pastoris)
is methylotrophic yeast belonging to the Ascomycetes group. It is characterized by its ability to have a
strong regulator promoter, its rapid growth, and its easy genetic manipulation; moreover, it has the
ability to perform eukaryotic post-translational modifications. P. pastoris characteristics have made
successful use possible for the production of many recombinant proteins, several of which are drugs
currently in clinical development [17,18].
Several kinds of Lf have been expressed in P. pastoris. Lf from humans, horses, pigs, goats, and
sheep has been expressed and purified. The expression levels obtained range from 2 to 1200 mg/mL,
and lactoferricin and lactoferampin, its bioactive peptide, have also been expressed in Pichia pastoris [17–19].
However, there are no reports of bLf expression in P. pastoris; bLf shares high homology among species,
and its antimicrobial potential has been tested in vivo and in vitro [20].
Due to the growing problem of antibiotic resistance, we focus our research on developing
technologies that allow for the obtainment of rLf with a powerful antimicrobial effect, which can be
used in the future as a replacement to current antibiotics. In the present study, we report for the first
time the expression, purification, and potential antimicrobial activity of recombinant bovine lactoferrin
(rbLf) in Pichia pastoris.
2. Results
2.1. Expression Vector Design and Synthesis
The vector pJ902sbLf (Figure 1) encodes for the bLf with optimized codon usage for P. pastoris
expression; it contains a selectable marker which confers Zeocin resistance. The synthetic
bovine lactoferrin (sbLf ) gene is derived from a bLf gene (GenBank accession No. EU812318) cloned by
García-Montoya et al. [15] and is under the control of the AOX1 promoter. Alkaline lysis extraction
and digestion of the synthetic plasmid pJ902sbLf by BamHI produced a linearized DNA fragment that
measured 5564 bp in length.
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Figure 1. Restriction map of pJ902sbLf. The vector containing a synthetic bovine lactoferrin (sbLf ) gene
for expression in P. pastoris yeast. The ZeoR gene was also included as a selectable marker.
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2.2. Molecular Analysis of Peptides Derived from Lactoferrin
An alignment analysis of the human and bovine LfcinAB was done (Figure 2) using a protein
alignment tool (UCFs Chimera, San Francisco, CA, USA). The overall amino-acid-based structure
identity was 43.7%.
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Figure 2. Comparison of bovine and human Lfcin moiety. Upper gray box represents amino acid
identity. Green boxes represents beta sheet and yellow box represent alfa sheet structure homology.
LFcin identification can be made on the basis of critically conserved basic residues—Lys in
positions 35, 41; Trp in 28; and Arginine in 37 and 40—represented by light-blue-colored letters in the
hydrophobicity modeling of Lfcin in Figure 3A,B. All have important roles in the interactions with
negatively charged surfaces, such as the lipopolysaccharide (LPS)-containing outer membrane (OM) of
Gram-negative bacteria (E. coli and Pseudomonas aeruginosa (Ps. aeruginosa)) and the teichoic acid layer
that surro nds the cytoplasmic membrane of Gram-positive bacteria (Staphylococcus aureus (S. aureus)).
The t rtiary structure of Lfcin is marke l i re 3C,D); however, a conserved central
α-helix s observed in the Lf structure.
Int. J. ol. Sci. 2016, 17, 902 3 of 11 
2.2. olecular naly is of Peptides erived fro   
n align ent analysis of the hu a  a  bovi e fcinAB was done (Figure 2) using a protein 
align ent tool ( Fs hi era, San Francisco, CA, USA). The overall a ino-acid-based structure 
identity as 43.7 . 
 
Figure 2. Co parison of bovine and hu an Lfcin oiety. pper gray box represents a ino acid 
identity. reen boxes represents beta sheet and yello  box represent alfa sheet structure ho ology. 
LFcin identification can be ade on the basis of critically conserved basic residues Lys in 
positions 35, 41; Trp in 28; and rginine in 37 and 40 represented by light-blue-colored letters in the 
hydrophobicity odeling of Lfcin in Figure 3 ,B. ll have i portant roles in the interactions ith 
negatively charge  surfaces, such as the lipopolysaccharide (LPS)-containing outer e brane ( ) 
of ra -negative bacteria (E. coli and Pseud onas aeruginosa (Ps. aeruginosa)) and the teichoic acid 
layer th  surrounds the cytoplas ic e bran  of ra -positive bacteria (S aphylococcus aureus  
(S. au eus)). 
The tertiary structure of Lfcin is ar dly different (Figure 3 , ); ho ever, a conserved central 
α-helix is observed in the Lf structure. 
 
Figure 3. Tertiary odel structure of hu an and bovine Lfcin. ( ) ydrophobicity odel hLfcin 
do ain (residues 17–41); P B I : 1BLF; and (B) bovine Lfcin (residues 17–31) odeled ith 1bLf as 
te plate; (C) predicted tertiary odel of hLfcin and ( ) bLfcin. Vie ed using Chi era soft are 
( CFs Chi era, San Francisco, C , S ). 
Figure 3. Tertiary model structure of human and bovine Lfcin. (A) Hydrophobicity model hLfcin
domain (residues 17–41); PDB ID: 1BLF; and (B) bovine Lfcin (residues 17–31) modeled with 1bLf as
template; (C) predicted tertiary model of hLfcin and (D) bLfcin. Viewed using Chimera software (UCFs
Chimera, San Francisco, CA, USA).
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2.3. Expression and Purification of Recombinant Bovine Lactoferrin (rbLf)
After P. pastoris transformation with pJ902sbLf vector, eight transformant clones were obtained.
Protein extracts were recovered, and dot blotting analyses after 72 h of induction revealed the presence
of lactoferrin in all clones; rbLf was detectable because of a very low concentration (0.5 mg/mL),
according to the detection of commercial bLf concentrations (Figure 4). The best-producing clone was
cultured in a batch fermentation using a shake flask, and the total protein extracts were recovered
and purified. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) confirmed the
presence of a band of about 80 kDa, according to lactoferrin weight (Figure 5). After the recombinant
protein induction on a large scale, we increased the expression level and obtained 3.5 g/L of rbLf.
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2.4. Antibacterial Activity of rbLf 
The antibacterial potential of rbLf was confirmed using non-fragmented and pepsin-digested 
rbLf. After incubation in a 96-well microplate, we established a bacterial growing inhibition percent 
based on a Rezarsurine indicator, which presents a blue coloration in the absence of bacterial growth. 
In the presence of a bacterial growth, it veers towards a pink color as a consequence of a REDOX 
reaction because of the bacterial metabolism. According to the different observed hues in the presence 
of Rezarsurine in the 96-well microplate, we set arbitrary values of bacterial growth inhibition percent 
Figure 4. Dot-immunoblotting analyses of recombinant bovine lactoferrin (rbLf) from induced clones.
Following 72 h of induction, proteins were harvested from supernatant and were spotted in a
polyvinylidene difluoride (PVDF) membrane. Lanes 1–8: protein samples of each clone; Lane 10:
commercial bovine lactoferrin (bLf) (0.5 mg/mL); Lane 11: commercial bLf (0.05 mg/mL); Lane 12:
protein extracts from native P. pastoris.
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Figure 5. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analyses of rbLf
purified from the yeast culture. Lane 1: commercial bLf; Lanes 2–3: purified rbLf.
2.4. Antibacterial Activity of rbLf
The antibacterial potential of rbLf was confirmed using non-fragmented and pepsin-digested
rbLf. After incubatio in a 96-well microplate, we established a bacterial growing inhibition percent
based on a Rezarsurine indicator, hich presents a blue coloration in the absence of bacterial growth.
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In the presence of a bacterial growth, it veers towards a pink color as a consequence of a REDOX
reaction because of the bacterial metabolism. According to the different observed hues in the presence
of Rezarsurine in the 96-well microplate, we set arbitrary values of bacterial growth inhibition percent
based on the pink hue. This data indicated a percentage of bacterial growth of 0%; the blue hue
indicated that the percentage of bacterial growth inhibition was 100%. Percentages were assigned
by reference to the visual color scale PANTONE® (Pantone Inc., Carlstadt, NJ, USA). The highest
percentage of inhibition was achieved in the presence of pepsin-digested rbLf by the action of its
bioactive peptide lactoferricin. An amount of 5.0 ng/mL was enough to achieve a growth inhibitory
effect. E. coli was totally inhibited using rbLfcin, while the strain S. aureus was able to inhibit 70% only.
For Ps. aeruginosa, a 40% inhibition using rbLfcin was obtained (Figure 6). One-way ANOVA showed
that the difference between the use of rbLfcin (Group A) and the use of antibiotic kanamycin (Group A)
to inhibit E. coli growth was not significant. rbLf (Group B) presented a significant difference about
rbLfcin. In the treatment against Ps. aeruginosa growth, a significant difference was observed between
kanamycin (Group A), rbLfcin (Group C), and rbLf (Group D). Finally, when rbLf was tested to inhibit
S. aureus growth, a major inhibition percentage using cbLfcin (Group A) was obtained; rbLf and rbLfcin
(Group B) showed a smaller inhibition percentage than cbLfcin; however, a lower percentage was
obtained with the use of antibiotic kanamycin (Group C). These results indicated that the best way to
use rbLf against microorganisms is in its digested form, rbLfcin, and the most susceptible bacterium
is E. coli.
Int. J. Mol. Sci. 2016, 17, 902 5 of 11 
  t  i  .              
  t  ercentage of bacterial growth inhibit on was 100%. Percentages were assigned by 
referenc  to he visual col r scale PANTONE® (Pantone Inc., Carlstadt, J, ).  i  
  i               
  l t i .    .  /         
t. . coli was totally inhibited using rbLfcin, while the strain S. aureus was able to inhibit 70% 
only. For Ps. aeruginosa, a 40% nhibition using rbLfcin was obtained (Figur  6). One-way ANOVA 
s owed that the difference between the use of rbLfcin (Group A) and the use of antibiotic kanamycin 
(Group A) to nhibit E. coli growth w s not significant. rbLf (Group B) presented a significan  
difference about rbLfcin. In the treatment ag inst Ps. aeru i osa growth, a significant difference was 
observed between kanamy   A), rbLfcin (Group C), and rbLf (Group D). Finally, whe  rbLf 
w s tested to inhibit S. aureus growth, a major hibition percentage using cbLfcin (Group A) was 
obtained; rbLf an  rbLfcin (Group B) showed a smaller inhibition perc ntage than cbLfcin; however, 
a low r percentage was obtained with the use f antibiotic kanamycin (Group C). These results 
indicated that the best way to use rbLf again  microorganisms is in its digested form, rbLf in, and 
the m st susceptible bacterium is E. coli. 
 
Figure 6. Antibacterial activity of rbLf. Bacterium were incubated in Luria-Bertani (LB) broth and 
treated with 5.0 ng/mL. Inhibition growth percentage was calculated relative to commercial bLf and 
commercial antibiotics. cbLf = commercial bovine lactoferrin; cbLfcin = commercial bovine lactoferricin; 
rbLf = recombinant bovine lactoferrin. rbLfcin = recombinant bovine lactoferricin; Kan = kanamycin. 
Group A belongs to treatment with highest percentage of inhibition, while group D belongs to treatment 
with lowest inhibition. Groups B and C are intermediate, however they are statistically different. 
3. Discussion 
Because of the indiscriminate use of antibiotics, the incidence of infections caused by resistant 
strains is currently rising. The development of new drugs has slowed, so the search and generation 
of new treatment strategies become an essential alternative [21]. Moreover, bLf has been used 
successfully to prevent and treat infectious diseases in newborns. When bLf is added to infant 
formulas, the incidence of infectious diseases of the respiratory tract and diarrhea decreases [22]. On 
the other hand, the oral administration of bLf generates a protective effect against necrotizing 
enterocolitis in very-low-birth-weight neonates [23]. These reports suggest that, in the future, rbLf 
could be used safely in neonates and will have a positive impact on their development and health. 
bLf displays potential antimicrobial activity, included against resistance strains. We produce and 
evaluate rbLf expressed in Pichia pastoris yeast and its antimicrobial effects. 
Figure 6. Antibacterial activity of rbLf. Bacterium were incubated in Luria-Bertani (LB) broth and
treated with 5.0 ng/mL. Inhibition growth percentage was calculated relative to commercial bLf and
commercial antibiotics. cbLf = commercial bovine lactoferrin; cbLfcin = commercial bovine lactoferricin;
rbLf = recombinant bovine lactoferrin. rbLfcin = recombinant bovine lactoferricin; Kan = kanamycin.
Group A belongs to treatment with highest percentage of inhibition, while group D belongs to treatment
with lowest inhibition. Groups B and C are intermediate, however they are statistically different.
3. Discussion
Because of the indiscriminate use of antibiotics, the incidence of infections caused by resistant
strains is currently rising. The development of new drugs has slowed, so the search and generation of
new treatment strategies become an essential alternative [21]. Moreover, bLf has been used successfully
to prevent and treat infectious diseases in newborns. When bLf is added to infant formulas, the
incidence of infectious diseases of the respiratory tract and diarrhea decreases [22]. On the other
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hand, the oral administration of bLf generates a protective effect against necrotizing enterocolitis in
very-low-birth-weight neonates [23]. These reports suggest that, in the future, rbLf could be used
safely in neonates and will have a positive impact on their development and health. bLf displays
potential antimicrobial activity, included against resistance strains. We produce and evaluate rbLf
expressed in Pichia pastoris yeast and its antimicrobial effects.
The methylotrophic yeast Pichia pastoris has been one of the mostly used production platforms of
recombinant proteins of pharmaceutical interest for over three decades [24]. The use of Pichia pastoris
as an expression system of therapeutic proteins gave us the advantage of combining the easy handling
and minimum growth requirements of a unicellular organism with the easily achievable genetic
modifications of a eukaryotic system.
An alignment analysis of the Lf-derived peptides was performed (Lfcin A and B chain); despite
its differences in nucleotide sequence, amino acid similarity was evident. This region retains high
homology among mammals and corresponds to amino acids 12–48 [25]. Chemically synthesized
fragments from Lfampin 268–284 and Lfampin 265–284 differ in only three amino acids
(265Asp-Leu267-Ile268), but its antimicrobial activity behavior is different [26]. Such structure may be
involved in recognizing bacterial membrane topology [27]. A single β-sheet strand in bovine Lficin
has not been observed in human Lfcin structure.
To express rbLf in Pichia pastoris KM71-H, we used the sbLf gene, which was modified to optimize
the codon usage. Expression of rbLf was under the control of the AOX1 promoter. BamHI site was
included at the end of the AOX1 terminator region for gene integration. To increase expression levels,
a batch fermentation was carried out; the highest expression levels of recombinant proteins under the
control of the AOX1 promoter have reached 22 g/L of intracellular proteins [28]. With the feature of
being a very strong promoter and being easily controllable by the change in the carbon source, the
AOX1 promoter is the most used regulatory element in the expression of heterologous proteins in
P. pastoris. After 72 h of induction, cell lysis, and purification from 1 L of culture medium, we obtained
an expression yield of 3500 mg/L of rbLf. In terms of yield, our expression level has been the highest
level of expression of rLf in Pichia pastoris. In fact, it places us above of the highest value reported,
corresponding to 1200 mg/L [29]; however, this level of expression was obtained from approximately
3 L of culture medium, three times more than that from the present experiment. Other contributions
have reported an rLf expression of 60 mg/L from Tibetan sheep [30], 12 mg/L from pigs [31], 40 mg/L
from horses [32], 40 mg/L from yaks [33], and a smaller level of expression of 2 mg/L from goat
lactoferrin [34].
Accumulation levels of heterologous proteins in yeast are altered by a variety of genetic and
physiological factors: the codon usage, the gene copy number, and the kind of promoter, translation
signals, and the final destiny of proteins. Secretion into the medium requires necessarily the use of a
signal sequence on the foreign protein to target it to the secretory pathway [35]. The use of a secretion
signal peptide has the advantage of excreting recombinant proteins to culture media without the need
for cell lysis; however, intracellular proteins are accumulated earlier than secreted proteins, so the
heterologous proteins can localize in a cytosolic soluble fraction and in an insoluble part protected by
inclusion bodies [36]. Surprisingly, our expression levels for rbLf were obtained without the addition
of signal sequence, unlike the other works cited above. Heterologous proteins derived from insoluble
fractions were released from inclusion bodies with urea, and they actually showed less degradation
than the proteins obtained from the soluble fraction.
Finally, we evaluate the antibacterial activity against Gram-negative bacteria E. coli and
Ps. aeruginosa and the Gram-positive bacteria S. aureus. Currently, Gram-negative bacteria are
becoming increasingly resistant to common antibiotics due to the presence of an outer membrane
(OM) that has a unique structure creating an impermeable layer, which provides protection against
antibiotic penetration [37]. In our last paper, we demonstrated that, unlike non-fragmented lactoferrin,
pepsin-digested rbLf has a higher antibacterial potential against E. coli [15]. The proteolytic digestion
of Lf by gastric pepsin releases a bioactive peptide of Lf called lactoferricin; because lactoferricin
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can alter the permeability of bacterial membrane, several studies support the idea that lactoferricin
presents higher antibacterial activity that non-fragmented lactoferrin [38]. We proved that digested
rbLf was able to inhibit 100% of growth of E. coli. Peptide insertion into the bilayer membrane of
E. coli generates a void in the hydrophobic core. In response to this void, the bacterium compensates
trying to fill it with the monolayer, which generates a thinning of the membrane with a consequent
dispersion of its components and finally the rupture [39,40]. Therefore, the use of rbLfcin against
this enterobacteria is the best way to inhibit its growth. On the other hand, Pseudomonas aeruginosa is
characterized to be extremely resistant to antibiotic agents [21]; it is an opportunist pathogen implicated
mainly in nosocomial infections, and its intrinsic resistance is attributed to its capability to growth
in biofilms. Moreover, the expression of efflux pumps allows the expulsion of antibiotics, making
it in a multi-resistant strain [41,42]. Despite the difficulty of inhibiting the growth of this bacterium,
surprisingly, our digested rbLf was able to inhibit 40% of growth; nevertheless, cbLf inhibited 60%
of bacteria growth. Therefore, these findings open a door to the study of the possible mechanisms
of action of Lf against this bacteria, which may be involved in part due to the iron sequester, or the
membrane lysis caused by the bioactive peptide lactoferricin. Glycosylation sites present in the rbLf
may also have a significant impact on the immunological mechanism and antimicrobial action of
lactoferrin. The glycosylation pattern can have differences between native and recombinant proteins;
however, more studies are needed to support this theory. In the end, the activity of rbLf against
Gram-positive bacteria S. aureus resulted in the inhibition of bacterial growth until 70%, both rbLf
as rbLfcin. The antimicrobial activity against S. aureus is implicated in the iron sequester. rLf has
shown the bacteriostatic activity of this bacteria [43]. Moreover, a recent study demonstrated that
recombinant lactoferricin can achieve the inhibition of S. aureus [17], so the lactoferricin mechanism
against Gram-positive bacteria should also be involved in the damage to the bacterial membrane by
penetration and consequent lysis.
4. Experimental Section
4.1. Strains, Enzymes, and Plasmids
Escherichia coli (E. coli) DH5α (Invitrogen®, Carlsbad, CA, USA) was used as a host for plasmid
propagation. Pichia pastoris (P. pastoris) KM71-H (provided by Cinvestav, Irapuato, Mexico) was used
for protein expression. We use the plasmid pJ902sbLf containing a synthetic gene which encodes for
the bovine lactoferrin DNA 2.0 in P. pastoris (DNA 2.0, Newark, CA, USA). All restriction enzymes were
purchased from Invitrogen® (USA). E. coli BL21DE3, S. aureus FRI37, and Ps. aeruginosa ATCC 27833
(provided by the Microbiology Laboratory at Facultad de Ciencias Químicas Universidad Autónoma
de Chihuahua) were used for the antimicrobial assay.
4.2. Media and Growth Condition
E. coli DH5α was cultured at 37 ˝C in Luria–Bertani (LB) broth (10 mg/L tryptone, 5 mg/L yeast
extract, 10 mg/L NaCl) and LB plates (15 mg/mL agar) supplemented with zeocin (37.5 µg/mL) as the
selective marker. P. pastoris was cultured at 30 ˝C and 250 rpm on YPD (1% yeast extract, 2% peptone,
2% dextrose) broth and YPD plates (20 mg/mL agar) supplemented with zeocin (175 mg/L) as the
selective marker. E. coli BL21DE3, S. aureus FRI137, and Ps. aeruginosa ATCC 27833 were cultured at
37 ˝C in LB broth.
4.3. Transformation of Pichia pastoris KM71-H
Expression vector pJ902sbLf was propagated in E. coli DH5α, and the plasmid was isolated from
the positive transformant clones. One microgram of linearized plasmid DNA was used to transform
P. pastoris KM71-H. The transformation was achieved by electroporation using a MicroPulser BioRad®
(BioRad, Hercules, CA, USA) according to the manufacturer’s instructions. After 3 days of incubation
in the presence of zeocin, the transformant clones were isolated for analyses.
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4.4. Expression of rbLf
To carry out the rbLf expression, a single colony of transformant clones were inoculated into 5 mL
of YPD medium supplemented with zeocin ( 175 mg/mL) and incubated at 250 rpm and 30 ˝C for 24 h,
and the cells were harvested by centrifugation and incubated at a seeding density of 0.1–0.2 optical
density (OD) in BMMY medium (100 mM potassium phosphate, pH 6.0, 1% yeast extract, 2% peptone,
1.3% Yeast Nitrogen Base (YNB), 400 µg/L biotin and 0.5% methanol) to induce the expression of rbLf.
Methanol was again added to a final concentration of 0.5% (v/v) every 24 h for 4 days to maintain
the induction according to the method described in [29]. After 4 days, the cells were harvested by
centrifugation at 5000 rpm for 10 min at 4 ˝C, and the pellet was resuspended in lysis buffer (10 mM
Tris-HCl, 100 mM NaCl at pH 6.5, 1X Protease Inhibitor Cocktail (cOmplete™, Mini, EDTA-free
Roche®, Pleasanton, CA, USA). The lysate was centrifuged at 5000 rpm for 5 min at 4 ˝C to obtain
soluble proteins. The insoluble pellet which contained inclusion bodies was washed in lysis buffer
with 6 M urea and incubated for 1 h on ice and centrifuged at 5000 rpm for 30 min at 4 ˝C to obtain
insoluble proteins. The soluble and insoluble protein extracts were collected and stored at ´20 ˝C for
further study.
4.5. Batch Fermentation
To increase the Lf accumulation, batch fermentation was achieved as follows: 200 mL of YPD
media supplemented with zeocin (175 mg/L) were inoculated with cells from a single colony of the
transformant clones and incubated overnight with shaking. Afterward, this culture was added to the
fermentor, which contained 1000 mL of BMMY induction media supplemented with zeocin (175 mg/L).
The culture was incubated at 30 ˝C on shaking. The induction stage was initiated after 24 h of growth
by adding 5% methanol each 24 h during 72 h to maintain the optimal expression of rbLf.
4.6. Purification of rbLf
After induction, protein extracts were collected as described below and purified by precipitation
and molecular exclusion. First crude extracts were precipitated with 28% of ammonium sulfate
resuspended and dialyzed against 100 vol of phosphate buffer. Semi-purified extracts were applied to
a sephacryl S-200 HR Column (GE Healthcare, Aurora, OH, USA) pre-equilibrated with four column
volumes of lysis buffer. Then, the column was washed with wash buffer (20 mM Tris-HCl and 150 mM
NaCl at pH 7.9). All of the fractions were collected and applied to a 12% SDS-PAGE analysis.
4.7. Dot-Blot Analysis
To assess Lf accumulation, the protein samples were spotted in a PVDF membrane
(ImmobilonTM-P Millipore, Darmstadt, Germany). The membrane was blocked with 1% Bovine Serum
Albumin (BSA) in Phosphate Buffered Saline (PBS) and shaken for 2 h. The rbLf was detected using an
anti-bLfHRP polyclonal antibody (United States Biological, Salem, MA, USA). The bound antibody
was detected using Diaminobenzidine (DAB)/Peroxide substrate system for color development.
The expression level was determined via dot-blot by densitometry in a KODAK® Gel Logic 100 System
(KODAK®, Rochester, NY, USA).
4.8. rbLf-Bioactive Peptide Recovery and Antimicrobial Assay
To test the antimicrobial activity, rbLf was digested with Pepsine (Invitrogen) to release the
bioactive peptides according to the protocol reported by Bellamy (1992) [44]. Approximately 2 ˆ 108
Colony Forming Units (UFC) per mL of each strain were incubated in a 96-well microplate (Corning,
Corning, NY, USA) containing LB broth with rbLf and pepsin-hydrolyzed rbLf. The final concentration
in each well was 5.0 ng/L of rbLf and pepsin-hydrolyzed rbLf. A portion of 0.01% resazurin was
added to each well as a REDOX indicator of the cell viability. Untreated strains cultured in LB were
used as a control. Commercial bLf (5 ng/mL) and kanamycin (60 ng/mL) were used as a control
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of growth inhibition. Cultures were incubated at 37 ˝C for 1 h and monitored by color change as a
consequence of the oxidative metabolism of the microorganisms.
4.9. Statistical Analysis
Antimicrobial activity tests were performed in triplicate; one-way unstacked ANOVA by the
Tukey test with a confidence level of 95% in MINITAB 16 was applied to determine if a significant
difference exists between different kinds of Lf to inhibit growth bacteria.
5. Conclusions
We successfully expressed high levels of functional rbLf in Pichia pastoris with antimicrobial
properties; our experience supports the hypothesis that structural differences in Lf and its derived
peptides exert antimicrobial properties. Furthermore, these advances will allow us to study
the molecular mechanisms of molecule adhesion and the immune cooperation of Lf against
microorganisms with clinical importance.
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